Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13698264 | 0.88 | CYP19A1 (0.56) | CYP19A1TSHRKMT2ASLC6A2SLC6A3 | |
| SCHEMBL13698259 | 0.88 | CYP19A1 (0.59) | CYP19A1TSHRKMT2ASLC6A2SLC6A3 | |
| SCHEMBL17583744 | 0.74 | KMT2A (0.66) | CYP19A1TSHRKMT2ASLC6A2SLC6A3 | |
| Phensuximide SCHEMBL35334 | 0.72 | KMT2A (1.00) | CYP19A1TSHRKMT2A | |
| Phensuximide SCHEMBL35333 | 0.72 | KMT2A (1.00) | CYP19A1TSHRKMT2A | |
| SCHEMBL13698249 | 0.71 | KMT2A (0.49) | CYP19A1TSHRKMT2ASLC6A4 | |
| SCHEMBL13698283 | 0.71 | CYP19A1 (0.54) | CYP19A1TSHRKMT2ASLC6A2SLC6A3 | |
| SCHEMBL7930709 | 0.71 | ADRA1A (0.55) | TSHRKMT2ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL7930713 | 0.71 | ADRA1A (0.55) | TSHRKMT2ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL983108 | 0.70 | CYP19A1 (0.52) | CYP19A1TSHRKMT2ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | CYP19A1 857/4885TSHR 1995/4885KMT2A 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.